Sigma Lithium's (SGML) mining and industrial operations remain unaffected by a preliminary judicial ruling that allegedly suspends its environmental licenses, the company said Monday.

Shares sank more than 16% as intraday trading volume jumped to over 3.3 million from the stock's daily average of roughly 1.8 million.

Novartis (NVS) said its phase 3 Harbor study evaluating delpacibart etedesiran in patients with myotonic dystrophy type 1 failed to meet its primary endpoint of video hand opening time.

Shares slumped 14% as intraday trading volume catapulted to over 6.8 million from a daily average of about 1.9 million.

Amgen's (AMGN) experimental heart drug olpasiran may still show a meaningful reduction in major cardiovascular events, even after Novartis' competing drug failed in a large study, UBS Securities said Monday in a report.

Nevertheless, Amgen shares dropped 9% as intraday trading volume climbed to 3.4 million from a daily average of about 2.7 million.

Price: 10.34, Change: -2.06, Percent Change: -16.59